SRR934977
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 104.82917214191852
- age_years
- 46
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.493
- G2M_CHECKPOINT+0.493
- HEDGEHOG_SIGNALING+0.396
- MITOTIC_SPINDLE+0.355
- WNT_BETA_CATENIN_SIGNALING+0.332
- PANCREAS_BETA_CELLS+0.317
- MYC_TARGETS_V1+0.275
- MTORC1_SIGNALING+0.267
- UV_RESPONSE_DN+0.252
- PROTEIN_SECRETION+0.220
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.314
- KRAS_SIGNALING_DN-0.267
- BILE_ACID_METABOLISM-0.257
- COAGULATION-0.243
- FATTY_ACID_METABOLISM-0.241
- ALLOGRAFT_REJECTION-0.229
- MYOGENESIS-0.225
- INTERFERON_GAMMA_RESPONSE-0.191
- COMPLEMENT-0.165
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.848 |
| 2 | 961CEC20-67F2-4615-8725-F35C12F0BC9B | — | — | 0.838 |
| 3 | ERR2598185 | fetal | fetal | 0.835 |
| 4 | MDT-AP-3334 | Med | Medulloblastoma | 0.830 |
| 5 | MNG257 | — | — | 0.826 |
| 6 | 86379365-5FD2-4655-8B3C-B8E0EE25EE92 | — | — | 0.822 |
| 7 | CB9E4206-E2F7-49EA-8FB2-E69E5BB3B018 | — | — | 0.821 |
| 8 | 3DA19761-6FF3-4E8C-AA0F-C04CE2CE7037 | — | — | 0.812 |
| 9 | 5EDF36F3-D370-4907-BDA1-8D5FD2B80513 | — | — | 0.810 |
| 10 | DF749F48-6A86-4640-9C62-31B4A7C5D1A9 | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.493 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.493 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.396 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.355 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.332 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.317 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.275 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.252 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.201 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.183 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.168 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.151 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.137 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.124 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.088 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.075 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.074 | Inavolisib | — uncovered |